E9P7TP6Lrj | 2143116-61-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: E9P7TP6Lrj
• 英文别名: 5-[4-[(1R)-1-aminoethyl]piperidin-1-yl]sulfonyl-2H-isoquinolin-1-one
• CAS: 2143116-61-2
• 化学式: C₁₆H₂₁N₃O₃S
• 分子量: 335.4
• InChiKey: OHJBYPWWCFTEPA-LLVKDONJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
  申请人：BioAxone BioSciences, Inc.

  公开号：US11198680B2

  公开（公告）日：2021-12-14

  BA-1049 (R) and its active metabolite are disclosed. Also disclosed are pharmaceutical formulations containing BA-1049 (R) or its active metabolite.

  本研究公开了 BA-1049 (R) 及其活性代谢物。还公开了含有 BA-1049 (R) 或其活性代谢物的药物制剂。
• RHO KINASE INHIBITOR BA-1049 (R) AND ACTIVE METABOLITES THEREOF
  申请人：BioAxone BioSciences, Inc.

  公开号：US20170313680A1

  公开（公告）日：2017-11-02

  The disclosure provides rho kinase inhibitor BA-1049(R), an hydroxy metabolite of BA-1049(R), and adipate salts and deuterated forms thereof, useful for treating CNS disorders and injuries.
• KINASE INHIBITORS FOR TREATMENT OF DISEASE
  申请人：BioAxone BioSciences, Inc.

  公开号：US20190015404A1

  公开（公告）日：2019-01-17

  Disclosed are therapeutic compositions including BA-1076 and/or BA-2057, methods of their use in the treatment of ophthalmological disorders. The therapeutic compositions may further include an IOP-lowering prostaglandin. The methods may further include administration of an IOP-lowering prostaglandin.
• [EN] KINASE INHIBITORS FOR TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE KINASE POUR LE TRAITEMENT DE MALADIES
  申请人：BIOAXONE BIOSCIENCES INC

  公开号：WO2019014322A1

  公开（公告）日：2019-01-17

  Disclosed are therapeutic compositions including BA-1076 and/or BA-2057, methods of their use in the treatment of ophthalmological disorders. The therapeutic compositions may further include an IOP- lowering prostaglandin. The methods may further include administration of an lOP-lowering prostaglandin.